ATHENS, Greece, August 6 /PRNewswire/ -- - Not for Release, Publication or Distribution Directly or Indirectly in or Into the United States, Canada, Australia, South Africa or Japan or any Other Jurisdiction in Which Such Publication or Distribution Would be Unlawful - This Announcement is not a Prospectus and is not an Offer to Sell or a Solicitation of any Offer to buy any Securities in the United States or in any Other Jurisdiction
Alapis S.A. ("Alapis" or "the Company") announces that, on 5 August, 2009, the Company's Board of Directors approved a share capital increase by way of pre-emptive rights for existing shareholders that will increase the Company's share capital by EUR 294,180,066.
The share capital increase will be effected through the issue of 980,600,220 new ordinary shares of a nominal value EUR0.30 each, with payment in cash.
Shareholders of Alapis will be entitled to one subscription right for each existing share held. The exercise of one subscription right will entitle the holder to subscribe for one new share at the proposed subscription price of EUR 0.46 per new share. In addition, those who will exercise their subscription rights will be entitled to subscribe for a number of additional new shares at the subscription price (oversubscription rights). The total gross proceeds will amount to approximately EUR 451.1 million.
The Company intends to use the net proceeds from the share capital increase to repay part of its existing short-term debt, finance expected working capital requirements and pursue targeted acquisitions of companies and other assets, in order to further support its growth strategy in the Greek and South-Eastern European healthcare markets.
Alapis has been informed that Lamda Partners L.P., a private equity fund, has irrevocably undertaken to participate in the share capital increase through one or more of its wholly owned subsidiaries by investing approximately EUR 90.2 million through the exercise of 196,120,044 rights, representing 20% of the new ordinary shares. Such rights will be acquired from Dr. Lavrentis Lavrentiadis or in the open market. The Company was also informed that Dr.Lavrentiadis is a director of the general partner of Lamda Partners L.P.
A syndicate of international firms composed of ABN AMRO, BofA Merrill Lynch, BNP PARIBAS, Deutsche Bank AG London Branch and Jefferies has agreed to subscribe or procure subscribers for any new shares which may remain unsubscribed at the end of the subscription period, subject to customary terms and conditions.
The Company's prospectus that will be prepared in relation to the share capital increase will be subject to approval by the Hellenic Capital Market Commission.
The Company will endeavour to complete the capital increase by the end of September, subject to obtaining all regulatory and other approvals in a Timely manner.
The decision of the Board of Directors is pursuant to the authority given to it by the second repeat Extraordinary General Meeting of Alapis' shareholders held on 29 September 2008.
Further inquiry note: Norbert Schmidt-Gollas firstname.lastname@example.org http://www.alapis.eu Alapis Aftokratoros Nikolaou str., No 2, p.c.176 71 Athens tel. +30-213-0175000-1 fax +30-210-9238460 emitter: ALAPIS S.A. Aftokratoros Nikalaou str. 2 17671 Athen phone: +30-213-0175000-1 FAX: +30-210-923-8460 mail: email@example.com WWW: http://www.alapis.eu sector: Pharmaceuticals ISIN: GRS322003013
|SOURCE ALAPIS S.A.|
Copyright©2009 PR Newswire.
All rights reserved